Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Hukkanen J et al. | The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. | 2015 | Br J Clin Pharmacol | pmid:26095142 |
de Graan AJ et al. | 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. | 2015 | Br J Clin Pharmacol | pmid:26119961 |
Kasichayanula S et al. | Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. | 2014 | Br J Clin Pharmacol | pmid:24837659 |
Størset E et al. | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28146606 |
Higashi T et al. | LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. | 2013 | Chem. Pharm. Bull. | pmid:23449202 |
Goodenough AK et al. | Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. | 2011 | Chem. Res. Toxicol. | pmid:21728364 |
DeGorter MK et al. | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. | 2013 | Circ Cardiovasc Genet | pmid:23876492 |
Jiang X et al. | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. | 2017 | Clin Pharmacol Drug Dev | pmid:27138546 |
Wollmann BM et al. | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. | 2017 | Clin Transl Sci | pmid:27991741 |
Kanebratt KP et al. | Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. | 2008 | Clin. Pharmacol. Ther. | pmid:18650803 |